Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Lynn Eaton
  1. 1London

    Researchers for the Cochrane Collaboration have found that mefloquine (Lariam) has more adverse effects than the two main alternatives for antimalaria prophylaxis.

    They looked at prophylactic regimens for visitors to countries where Plasmodium falciparum has developed resistance to chloroquine (Cochrane Database of Systematic Reviews 2009;(4):CD006491, doi:10.1002/14651858.CD006491.pub2). Their review looked at the efficacy, safety, and tolerability of three regimens: atovaquone-proguanil (Malarone), doxycycline, and mefloquine.

    On safety, the authors said that the main problem …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular